Switch studies in virologically suppressed patients

Switch to RAL-containing regimen
Canadian Study: Switch ENF to RAL
Original article : AIDS. 2008 Jun 19;22(10):1224-6 – M Harris
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Pilot, open-label study
  • 35 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 50 c/mL
  • Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
    • ENF had been administered for a median of 25 months
    • HIV-1 RNA was < 50 c/mL for a median of 24 months
    • Salvage regimen: 1 to 4 NRTIs, 1 NNRTI in 6 patients, 1 to 2 PIs
  • Median follow-up of 7 months (range 1-13 months)
    • 34/35 patients maintained HIV-1 RNA < 50 c/mL
    • 1 single blip at 60 c/mL
    • ENF-related injection site reactions resolved in all patients
    • RAL was well tolerated

 

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei